Zentalis Reports 15.9-Month Median Overall Survival With Azenosertib in Cyclin E1-Positive Ovarian Cancer Trial

Bitget2026/10/23 14:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zentalis Pharmaceuticals presented interim DENALI Part 1b results for investigational ovarian cancer treatment azenosertib at the ESMO Congress 2026.
Patients with Cyclin E1-positive platinum-resistant ovarian cancer had longer median overall survival than those with Cyclin E1-negative tumors.
The findings support Cyclin E1 protein expression as a patient-selection biomarker for azenosertib.
Safety remained consistent with prior reports, with treatment-related adverse events prompting dose changes or discontinuation in some patients.
Azenosertib remains under development in the registration-intended DENALI Part 2 study and ASPENOVA Phase 3 confirmatory trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231015PRIMZONEFULLFEED9851795) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zentalis Reports 15.9-Month Median Overall Survival With Azenosertib in Cyclin E1-Positive Ovarian Cancer Trial

You may also like

Crypto prices